---
document_datetime: 2026-01-09 13:57:50
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/praluent-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: praluent-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.3363596
conversion_datetime: 2026-01-10 11:17:52.9945
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Praluent

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 17/10/2025                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000295839                     | PRODUCTS - C.I.z Other variation - Accepted C.I.z - to update sections 4.8 and 5.1 of the SmPC of Praluent (alirocumab) as follows: LDL-C values : change of the position of unit to mmol/L (mg/dL) in sections 4.8 and 5.1 of SmPC. Update in the population of SYDNEY study based on MSC14864 Clinical Study Report (in section 5.1 of SmPC). In addition, the contact details for local representatives for Iceland and Italy in section 6 of the Package Leaflet were updated and UK (Northern Ireland) was deleted. Finally, for Praluent 300 mg solution for injection in pre-filled pen the Annex A was updated in order to differentiate the new buttonless prefilled pens (EU/1/15/1031/021 & EU/1/15/1031/022) from the previously approved ones (EU/1/15/1031/019 & EU/1/15/1031/020).   |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000302713 | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 15/10/2025 | N/A |
| Variation type IB / EMA/VR/0000280943 | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 28/07/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Other changes - Accepted B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted   |            |      |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|
| Variation type II / EMA/VR/0000245060 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.2 and 5.1 of the SmPC in order to update the posology to allow all                                                                                                                                                                                                                                                                        | 27/03/2025 | SmPC |

<div style=\"page-break-after: always\"></div>

|                                       | dose strengths for treatment initiation and to update clinical efficacy and safety information, based on currently available data.   |            |     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000253639 | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.z Other variation - Accepted                          | 13/03/2025 | N/A |